secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAIA Biotechnology, Inc. (MAIA)
CIK:        0001878313
Form:       8-K
Filed at:   2025-04-01T23:59:59+00:00
Accession:  0001641172-25-002001
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MAIA Biotechnology details 2025 clinical milestones; potential FDA filings in 2026 for THIO
--------------------------------------------------------------------------------

- Lead compound THIO is the only clinical-stage telomere-targeting anticancer agent.
- Phase 2 THIO-101 expansion underway; potential accelerated approval filing in 2026.
- Phase 3 THIO-104 set to begin mid-2025; potential full approval filing in 2026.
- Multiple THIO trials planned in additional cancer indications.
- Significant market opportunity in hard-to-treat cancers with unmet medical needs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1878313/000164117225002001/0001641172-25-002001-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1878313/000164117225002001/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-002001

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer